StockNews.com began coverage on shares of La Jolla Pharmaceutical (NASDAQ:LJPC – Get Rating) in a research note issued to investors on Thursday. The firm set a “buy” rating on the biopharmaceutical company’s stock. Separately, Zacks Investment Research downgraded La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a report on Wednesday, January […]